The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

EHBP1  -  EH domain binding protein 1

Homo sapiens

Synonyms: EH domain-binding protein 1, HPC12, KIAA0903, NACSIN
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of EHBP1

  • Patients with Paget's disease of bone were treated with oral disodium dihydrogen ethylidene-1-hydroxy-1,1-bisphosphonate (EHBP), a drug that is known to stimulate renal tubular reabsorption of orthophosphate (Pi) [1].
  • CONCLUSIONS: EHBP has the advantage of clinical acceptance as a therapeutic agent for other purposes and its toxicity has been well studied [2].

High impact information on EHBP1


Chemical compound and disease context of EHBP1

  • Both CBMIDA and EHBP were effective in excreting DU, reducing DU concentrations in organs, and preventing DU-induced toxicity, and CBMIDA was superior to EHBP, particularly in the prevention of renal dysfunction [5].

Biological context of EHBP1

  • In a series of experiments with animals the effectiveness of various preparations and treatment plans was compared Action of 1-hydroxyethyliden-1, 1-bisphosphonic acid (EHBP, xydiphon) on calcium metabolism and bone tissue in human was the subject of experiments with long-term head-down tilt (HDT) [6].

Anatomical context of EHBP1

  • After 2 weeks of oral EHBP, the increase in the Pi concentration in patients' erythrocytes was 31% compared with 64% in plasma [1].
  • It is therefore unlikely that this effect is due to an immediate action of EHBP on the luminal face of the renal brush border Pi transporter [1].
  • These cells were seeded onto slices of human dentin which had been soaked in either saline (control), or solutions of 10(-5) M 1-hydroxyethylidene-1, 1-bisphosphonic acid (EHBP), 10(-6) M dichloromethylene bisphosphonic acid (Cl2MBP), or 10(-6) M gallium nitrate [7].

Associations of EHBP1 with chemical compounds

  • Recently, the focus has turned to drugs that have been used successfully in the treatment of a variety of other diseases, for example the iron chelating drug deferiprone or 1,2-dimethyl-3-hydroxypyrid-4-one (L1), which is used in thalassaemia and ethane-1-hydroxy-1,1-bisphosphonate (EHBP), which is used in osteoporosis [8].
  • RESULTS: The present study shows that one prompt injection of EHBP reduced uranium deposition in kidneys by a factor of five after acute intramuscular contamination in rats [2].
  • MATERIALS AND METHODS: The efficacy of ethane-1-hydroxy-1,1-bisphosphonate (EHBP), already in use as a therapeutic agent, was investigated in animal experiments [2].
  • Local treatments by EHBP seemed more efficient than those by DTPA in decorporating uranium and plutonium but the complexes radionuclide-EHBP seemed to diffuse through the skin more than the radionuclide-DTPA complexes if the skin was not rinsed after application of the chelating agent [9].
  • One group was kept as the control (no injected DU) group, which consisted of five intact, five with CBMIDA, and five with EHBP administration [5].

Other interactions of EHBP1

  • High expression of EHD2 or EHBP1 in intact cells mediates extensive actin reorganization [4].

Analytical, diagnostic and therapeutic context of EHBP1

  • Intravenous EHBP caused a more rapid increase in plasma Pi, but maximum hyperphosphatemia was not observed until 7-11 days after treatment commenced [1].


  1. Cellular phosphate metabolism in patients receiving bisphosphonate therapy. Challa, A., Noorwali, A.A., Bevington, A., Russell, R.G. Bone (1986) [Pubmed]
  2. Efficacy of ethane-1-hydroxy-1,1-bisphosphonate (EHBP) for the decorporation of uranium after intramuscular contamination in rats. Henge-Napoli, M.H., Ansoborlo, E., Chazel, V., Houpert, P., Paquet, F., Gourmelon, P. Int. J. Radiat. Biol. (1999) [Pubmed]
  3. Role of EHD1 and EHBP1 in perinuclear sorting and insulin-regulated GLUT4 recycling in 3T3-L1 adipocytes. Guilherme, A., Soriano, N.A., Furcinitti, P.S., Czech, M.P. J. Biol. Chem. (2004) [Pubmed]
  4. EHD2 and the novel EH domain binding protein EHBP1 couple endocytosis to the actin cytoskeleton. Guilherme, A., Soriano, N.A., Bose, S., Holik, J., Bose, A., Pomerleau, D.P., Furcinitti, P., Leszyk, J., Corvera, S., Czech, M.P. J. Biol. Chem. (2004) [Pubmed]
  5. Effects of pH on du intake and removal by CBMIDA and EHBP. Fukuda, S., Ikeda, M., Nakamura, M., Yan, X., Xie, Y. Health physics (2007) [Pubmed]
  6. Influence of bisphosphonates on calcium metabolism and bone tissue during simulation of the physiological effects of microgravity. Grigoriev, A., Morukov, B., Stupakov, G., Bobrovnik, E. Journal of gravitational physiology : a journal of the International Society for Gravitational Physiology. (1998) [Pubmed]
  7. Effect of bisphosphonates and gallium on dentin resorption in vitro. Liewehr, F.R., Craft, D.W., Primack, P.D., Kulild, J.C., Turgeon, D.K., Sutherland, D.E., Schuster, G.S., Pashley, D.H. Endodontics & dental traumatology. (1995) [Pubmed]
  8. Chelating agents used for plutonium and uranium removal in radiation emergency medicine. Fukuda, S. Current medicinal chemistry. (2005) [Pubmed]
  9. Contamination and decontamination of rat and human skin with plutonium and uranium, studied with a Franz's chamber. Tymen, H., Gerasimo, P., Hoffschir, D. Int. J. Radiat. Biol. (2000) [Pubmed]
WikiGenes - Universities